[ad_1]
Trump, with the prior approval of the hydroxychloroquine catalyzed a huge change in the South Asian country, spurring the world’s largest producer of the drugs to do much more of it, to prescribe the front line of the health care workers treating the virus and is implemented as a diplomatic tool, despite the growing evidence against the use of the drug for COVID-19.
Trump said Monday that he was taking hydroxychloroquine as a measure of protection against the virus. The Food and Drug Administration, however, has warned against its use outside of hospitals, due to the risk of serious heart problems.
The Indian policy in the decades of drugs, used to prevent malaria and to treat lupus and rheumatoid arthritis, has changed dramatically after Trump twitter in March that the drug, used together with an antibiotic, it can be “game changers” in the fight against the pandemic. India’s ministry of health quickly approved as a prophylactic for the care of the health of workers and other people at high risk of infection, and as a treatment for critically ill patients.
Officials in Mumbai, even drew up a plan to manage the hydroxychloroquine to thousands of slum dwellers, as a preventive measure against the virus.
Indian health officials have declined repeated requests for comments, the limitation of health communications journal of informative sessions, the last of which occurred on the 11th of May.
The rules say that drugs such as hydroxychloroquine be used only after a rigorous scientific and ethical review, ongoing supervision by an ethics committee and ensure informed consent — neither of which happened with HCQ, according to Dr. Amar Jesani, a physician with expertise in ethics.
The Mumbai proposal was finally shelved in the midst of the questions of the ethics of the administration of HCQ, as the drug is known, without first subjecting it to clinical trials. Even so, the government of India has recommended more and more people are using it, in contravention of 2017 rules for the emergency use of drugs not tested, Jesani said.
India initially banned HCQ exports, but lifted the ban after Trump threatened “retaliation.” At the same time, the government of India ordered the manufacturers to ramp up production of 1.2 million to 3 million tablets a month, causing the shares of the company to skyrocket. From the united states to Australia, the sales increased.
Officials have said that the Indian plantations could increase the capacity of growth of trees of cinchona, whose bark contains the compound quinine, which has been used to treat malaria since the 1860s. Quinine can also be made synthetically.
The government of India itself bought 100 million of HCQ tablets, according to government data, to distribute to the states and to donate to countries such as Afghanistan, Myanmar and the Dominican Republic.
India is the world’s largest producer of generic drugs, a fast-growing industry that has brought down prices of pharmaceutical products worldwide. During the crisis of HIV/Aids, India plays a similar role as in the coronavirus of the pandemic, the boost to global supplies of life-saving medicines.
The problem this time, experts say, is that the hydroxychloroquine hype is based on a flimsy survey with little or no evidence that it prevents or treats COVID-19.
Even so, a strong increase in demand has reduced supplies to patients with lupus and rheumatoid arthritis.
India was quick orientation has also prevented the scientific tests that could determine if the benefits of taking HCQ outweigh the risks.
“We have to make a judgement. I think that is the right way to come to answer this question. But the (government) did that our job is more difficult,” said Dr. Bharath Kumar, whose team has proposed a trial.
Meanwhile, the evidence against the use of HCQ for the coronavirus is growing.
A study conducted in the united states of 368 patients in veterans ‘ hospitals, the largest study yet the review of HCQ value as a coronavirus antidote, found no benefit and even more deaths among those who received the drug.
The government of India’s own assessment, 19 drug found that the HCQ was not the most promising. A task force to note that, while the HCQ was readily available, the strength of the scientific evidence for the mechanism of action was quite low.
With more than 101,000 cases and 3,163 deaths, the virus has not yet overwhelmed the India’s limited health care system. But that is beginning to change in some hot spots such as the strict requirements of weeks-of the national character of lock security starts with ease, which allows a greater mobility of the country’s 1.3 billion people.
In no place is this more clear that in Maharashtra, the coastal state in the central India that carries a third of India from the virus of the workload. The state of medical education and research of the agency has been the administration of HCQ patients in public hospitals and clinics, according to court records.
Agency chief Dr. Tatyarao P. Lahane said protocols established by the government of India were being followed and refused to answer most questions.
Dr. Shriprakash Kalantri, Mahatma Gandhi Institute of Medical Sciences, in Maharashtra, said the government was recommending HCQ for “off label”, or non-authorized use, which means that patients should be informed that “there is a small but significant risk that you could hurt.”
“If there is evidence backed by a solid clinical trials, then why are the scientific bodies pushing this drug and giving the impression to the public that this is a magic solution, and this is your last hope?” Kalantri said.
This story has been published from a cable of the agency of power without modifications in the text.
.
[ad_2]
